Vanguard Group Inc. Has $264.93 Million Stock Holdings in CG Oncology, Inc. $CGON

Vanguard Group Inc. increased its position in shares of CG Oncology, Inc. (NASDAQ:CGON) by 11.4% during the 3rd quarter, Holdings Channel reports. The fund owned 6,577,281 shares of the company’s stock after buying an additional 670,770 shares during the quarter. Vanguard Group Inc. owned 0.09% of CG Oncology worth $264,933,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. AQR Capital Management LLC acquired a new stake in CG Oncology in the first quarter worth $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of CG Oncology by 18.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock valued at $876,000 after buying an additional 5,442 shares in the last quarter. Millennium Management LLC raised its stake in CG Oncology by 139.4% during the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock worth $14,597,000 after buying an additional 347,055 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in CG Oncology by 42.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock worth $4,393,000 after acquiring an additional 53,461 shares in the last quarter. Finally, Winthrop Capital Management LLC acquired a new position in CG Oncology in the second quarter valued at about $38,000. Institutional investors own 26.56% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Morgan Stanley set a $93.00 price target on CG Oncology in a research report on Friday, January 9th. HC Wainwright raised their target price on shares of CG Oncology from $75.00 to $80.00 and gave the stock a “buy” rating in a report on Friday. Royal Bank Of Canada lifted their price target on shares of CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Truist Financial increased their price objective on shares of CG Oncology from $66.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a report on Monday, January 12th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, CG Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $69.00.

Insider Activity at CG Oncology

In other news, Director James Mulay sold 11,145 shares of the firm’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $52.47, for a total value of $584,778.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.40% of the stock is currently owned by corporate insiders.

CG Oncology Stock Up 4.8%

NASDAQ:CGON opened at $58.80 on Friday. The company has a market cap of $4.74 billion, a P/E ratio of -28.41 and a beta of 1.32. CG Oncology, Inc. has a twelve month low of $14.80 and a twelve month high of $60.00. The business has a 50 day moving average price of $50.42 and a two-hundred day moving average price of $42.20.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, February 27th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.10. The business had revenue of $2.32 million during the quarter. As a group, analysts anticipate that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.